Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Erythropoietin alpha - Dong-A ST

Next Previous
Drug Profile

Erythropoietin alpha - Dong-A ST

Alternative Names: DA-3285; EPO - Dong-A ST; Eporon; Erythropoietin - Dong-A; Erythropoietin alfa

Latest Information Update: 28 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dem Ilac; Dong-A Pharmaceutical
  • Class Antianaemics; Polyethylene glycols; Recombinant erythropoietins; Recombinant fusion proteins
  • Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia
  • Discontinued Ischaemia

Most Recent Events

  • 28 Sep 2022 Discontinued - Phase-II for Ischaemia in South Korea (IV) (Dong-A Pharmaceutical pipeline, September 2022)
  • 15 Jul 2016 Phase-II clinical trials in Ischaemia in South Korea (IV) (NCT02603406)
  • 03 Feb 2016 Dong-A ST and Ajou University School of Medicine plan the phase II NIMBUS trial for Stroke in South Korea (IV) (NCT02603406)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top